November 18, 2020

Enhancing the Culture of Cell Line Development

Stable cell lines are widely used in a wide range application, including biologics production, drug screening, and gene functional studies. The COVID-19 pandemic led to disruptions in all phases of drug development, and it has compelled many pharmaceutical companies and clinical research organizations (CROs) to put their clinical studies on hold. The new government policies, stay-at-home orders, social distancing norms, and widespread anxiety are among the prime challenges faced by researchers conducting the ongoing studies.

FOR MORE DETAILS DOWNLOAD SAMPLE PDF COPY

The growth of the cell line development market is attributed to factors such as increasing adoption of regenerative medicines, rising prevalence of cancer in the world, and mounting investments in R&D by pharmaceutical and biotechnology companies. However, the risks associated with cell line contamination hinder the growth of this market.

Merck KGaA, Thermo Fisher Scientific Inc., Selexis SA (JSR Corporation), BioFactura, Inc., Corning Incorporated, Sartorius AG, Lonza, GENERAL ELECTRIC, LakePharma, Inc., and WuXiAppTec Group are among the leading companies operating in the global cell line development industry.

The cell line is an established cell culture, wherein the cells multiply in the apt growth medium and space for growth. Different cell lines are made from different cells. Cell lines enable stepwise alterations in the structure, physiology, and genetic makeup of cells under a customized environment. The cell line development market growth is mainly attributed to increasing adoption of regenerative medicines, rising prevalence of cancer across the globe, and soaring investments in R&D by pharmaceutical and biotechnology companies. Moreover, consistent research in drug discovery activities is further expected to foster market growth during the forecast period. However, the risk of cell line contamination is restricting the market growth.

North America has been witnessing growing number of COVID-19 cases since the viral outbreak. According to Worldometer, as of September 2, 2020, the number of cases has reached to 6,335,244, with 191,058 deaths, in the US. The pharmaceutical companies and research institution have shifted their research activities in finding vaccine for COVID-19, thereby putting the development of other therapeutics on hold.

DOWNLOAD SAMPLE PDF COPY